Abstract
The macrocycles representing a unique chemical structure bridging conventional small molecules and large biomolecules, have attracted more and more attention in drug discovery over the past decade, and tremendous progress has been made toward the macrocyclization synthesis and structure diversification recently. Because of their favored size, flexibility and complexity, macrocycles can engage previously undruggable targets through numerous and spatially distributed binding interactions, and offer many privileged features including high potency, prominent selectivity, as well as favorable pharmacokinetics properties, and unique intellectual property(IP) space, and even safety profiles, etc. Currently around 70 macrocyclic molecules have been approved for clinical therapy, over 76 macrocycles are being evaluated in clinical trials from phase I to phase III. It is believed that the macrocycles will play more and more important role in the future, and provide very distinctive and promising opportunities for drug discovery along with the development of synthetic methodology, phenotypical screening, and computational studies.
Keywords: Macrocycle, Macrocyclic peptide, Macrolide, Macrocyclization, Infection disease, Oncology, Drug discovery.
Current Pharmaceutical Design
Title:Macrocyclic Compounds: Emerging Opportunities for Current Drug Discovery
Volume: 22 Issue: 26
Author(s): Lisha You, Rui An, Kun Liang, Bo Cui and Xinhong Wang
Affiliation:
Keywords: Macrocycle, Macrocyclic peptide, Macrolide, Macrocyclization, Infection disease, Oncology, Drug discovery.
Abstract: The macrocycles representing a unique chemical structure bridging conventional small molecules and large biomolecules, have attracted more and more attention in drug discovery over the past decade, and tremendous progress has been made toward the macrocyclization synthesis and structure diversification recently. Because of their favored size, flexibility and complexity, macrocycles can engage previously undruggable targets through numerous and spatially distributed binding interactions, and offer many privileged features including high potency, prominent selectivity, as well as favorable pharmacokinetics properties, and unique intellectual property(IP) space, and even safety profiles, etc. Currently around 70 macrocyclic molecules have been approved for clinical therapy, over 76 macrocycles are being evaluated in clinical trials from phase I to phase III. It is believed that the macrocycles will play more and more important role in the future, and provide very distinctive and promising opportunities for drug discovery along with the development of synthetic methodology, phenotypical screening, and computational studies.
Export Options
About this article
Cite this article as:
You Lisha, An Rui, Liang Kun, Cui Bo and Wang Xinhong, Macrocyclic Compounds: Emerging Opportunities for Current Drug Discovery, Current Pharmaceutical Design 2016; 22 (26) . https://dx.doi.org/10.2174/1381612822666160204114838
DOI https://dx.doi.org/10.2174/1381612822666160204114838 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
Vascular Disease Prevention (Discontinued) Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Effects of Atorvastatin on Cerebral Blood Flow in Middle-Aged Adults at Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Preface [Hot topic: Autoimmunity (Executive Editors: D. Stahl and W. Sibrowski)]
Current Pharmaceutical Design ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Vascular Damage in Obesity and Diabetes: Highlighting Links Between Endothelial Dysfunction and Metabolic Disease in Zebrafish and Man
Current Vascular Pharmacology Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Roles of CLR/RAMP Receptor Signaling in Reproduction and Development
Current Protein & Peptide Science Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology Cardio-Renal-Anemia Syndrome: A Link Between Erythropoietin, Dimethylarginine and Homocysteine
Current Medicinal Chemistry Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews Role of Perindopril in the Prevention of Stroke
Recent Patents on Cardiovascular Drug Discovery